# A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Source: https://onco.cc/trials/nct05678270/  
OnCo record `nct05678270` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ICP-192 in biliary tract cancer, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.

## Summary

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma is a phase 2 interventional study registered as NCT05678270 by Beijing InnoCare Pharma Tech Co., Ltd., with 70 participants planned, started 2022-11-15 and due to reach its primary completion in 2026-05. Interventions recorded: ICP-192.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05678270
- Phase: 2
- Setting: A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05678270: https://clinicaltrials.gov/study/NCT05678270

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05678270.json